{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T15:59:01Z","timestamp":1790611141339,"version":"4.1.0"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T00:00:00Z","timestamp":1785196800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T00:00:00Z","timestamp":1785196800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s12325-026-03719-9","type":"journal-article","created":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T08:01:39Z","timestamp":1785225699000},"page":"4936-4952","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Real-World Outcomes of Vosoritide Treatment in Chinese Children with Achondroplasia: The Retrospective Cohort COREV Study"],"prefix":"10.1007","volume":"43","author":[{"given":"Lifen","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaofei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiwen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenli","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuan","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hanbing","family":"Shang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yirong","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanyan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhidong","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoyu","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2436-7857","authenticated-orcid":false,"given":"Zhiya","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,28]]},"reference":[{"key":"3719_CR1","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1002\/ajmg.1320590218","volume":"59","author":"IM Orioli","year":"1995","unstructured":"Orioli IM, Castilla EE, Scarano G, Mastroiacovo P. Effect of paternal age in achondroplasia, thanatophoric dysplasia, and osteogenesis imperfecta. Am J Med Genet. 1995;59:209\u201317.","journal-title":"Am J Med Genet"},{"key":"3719_CR2","unstructured":"[Experts consensus on diagnosis and treatment of achondroplasia]. Zhonghua Er Ke Za Zhi. 2021;59:545\u201350."},{"key":"3719_CR3","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1002\/dvdy.24479","volume":"246","author":"DM Ornitz","year":"2017","unstructured":"Ornitz DM, Legeai-Mallet L. Achondroplasia: development, pathogenesis, and therapy. Dev Dyn. 2017;246:291\u2013309.","journal-title":"Dev Dyn"},{"key":"3719_CR4","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-018-0972-6","volume":"14","author":"RM Pauli","year":"2019","unstructured":"Pauli RM. Achondroplasia: a comprehensive clinical review. Orphanet J Rare Dis. 2019;14:1.","journal-title":"Orphanet J Rare Dis"},{"key":"3719_CR5","doi-asserted-by":"publisher","first-page":"231","DOI":"10.5435\/00124635-200904000-00004","volume":"17","author":"ED Shirley","year":"2009","unstructured":"Shirley ED, Ain MC. Achondroplasia: manifestations and treatment. J Am Acad Orthop Surg. 2009;17:231\u201341.","journal-title":"J Am Acad Orthop Surg"},{"key":"3719_CR6","first-page":"45","volume":"2","author":"Y Wang","year":"2013","unstructured":"Wang Y, Liu Z, Zhao H, Zhou X, Cui Y, Han J. Advances in research on and diagnosis and treatment of achondroplasia in China. Intractable Rare Dis Res. 2013;2:45\u201350.","journal-title":"Intractable Rare Dis Res"},{"key":"3719_CR7","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1136\/adc.2010.189092","volume":"97","author":"MJ Wright","year":"2012","unstructured":"Wright MJ, Irving MD. Clinical management of achondroplasia. Arch Dis Child. 2012;97:129\u201334.","journal-title":"Arch Dis Child"},{"key":"3719_CR8","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1016\/S0140-6736(07)61090-3","volume":"370","author":"WA Horton","year":"2007","unstructured":"Horton WA, Hall JG, Hecht JT. Achondroplasia. Lancet. 2007;370:162\u201372.","journal-title":"Lancet"},{"key":"3719_CR9","doi-asserted-by":"publisher","DOI":"10.1186\/s10195-019-0541-3","volume":"21","author":"GA Hosny","year":"2020","unstructured":"Hosny GA. Limb lengthening history, evolution, complications and current concepts. J Orthop Traumatol. 2020;21:3.","journal-title":"J Orthop Traumatol"},{"key":"3719_CR10","first-page":"238","volume":"10","author":"R Aldegheri","year":"2001","unstructured":"Aldegheri R, Dall\u2019Oca C. Limb lengthening in short stature patients. J Pediatr Orthop B. 2001;10:238\u201347.","journal-title":"J Pediatr Orthop B"},{"key":"3719_CR11","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1159\/000446958","volume":"86","author":"M Miccoli","year":"2016","unstructured":"Miccoli M, Bertelloni S, Massart F. Height outcome of recombinant human growth hormone treatment in achondroplasia children: a meta-analysis. Horm Res Paediatr. 2016;86:27\u201334.","journal-title":"Horm Res Paediatr"},{"key":"3719_CR12","doi-asserted-by":"publisher","first-page":"314","DOI":"10.1038\/s41574-024-01074-9","volume":"21","author":"R Savarirayan","year":"2025","unstructured":"Savarirayan R, Hoover-Fong J, Ozono K, et al. International consensus guidelines on the implementation and monitoring of vosoritide therapy in individuals with achondroplasia. Nat Rev Endocrinol. 2025;21:314\u201324.","journal-title":"Nat Rev Endocrinol"},{"key":"3719_CR13","doi-asserted-by":"publisher","first-page":"684","DOI":"10.1016\/S0140-6736(20)31541-5","volume":"396","author":"R Savarirayan","year":"2020","unstructured":"Savarirayan R, Tofts L, Irving M, et al. Once-daily, subcutaneous vosoritide therapy in children with achondroplasia: a randomised, double-blind, phase\u00a03, placebo-controlled, multicentre trial. Lancet. 2020;396:684\u201392.","journal-title":"Lancet"},{"key":"3719_CR14","doi-asserted-by":"publisher","first-page":"2443","DOI":"10.1038\/s41436-021-01287-7","volume":"23","author":"R Savarirayan","year":"2021","unstructured":"Savarirayan R, Tofts L, Irving M, et al. Safe and persistent growth-promoting effects of vosoritide in children with achondroplasia: 2-year results from an open-label, phase\u00a03 extension study. Genet Med. 2021;23:2443\u20137.","journal-title":"Genet Med"},{"key":"3719_CR15","doi-asserted-by":"publisher","first-page":"2057","DOI":"10.1007\/s40265-021-01623-w","volume":"81","author":"S Duggan","year":"2021","unstructured":"Duggan S. Vosoritide: first approval. Drugs. 2021;81:2057\u201362.","journal-title":"Drugs"},{"key":"3719_CR16","unstructured":"European Medicines Agency. Voxzogo (Vosoritide). Product information. BioMarin Pharmaceutical Inc. 2025"},{"key":"3719_CR17","doi-asserted-by":"publisher","DOI":"10.1016\/j.gimo.2023.100223","volume":"1","author":"J Hoover-Fong","year":"2023","unstructured":"Hoover-Fong J, Irving M, Bacino C, et al. P194: persistence of growth promoting effects in children with achondroplasia over seven years: update from phase\u00a0II extension study with vosoritide. Genet Med Open. 2023;1:100223.","journal-title":"Genet Med Open"},{"key":"3719_CR18","first-page":"1103","volume":"61","author":"XN Zong","year":"2023","unstructured":"Zong XN, Li H, Zhang YQ. Wu HH [Updated growth standards for Chinese children under 7\u00a0years of age]. Zhonghua Er Ke Za Zhi. 2023;61:1103\u20138.","journal-title":"Zhonghua Er Ke Za Zhi"},{"key":"3719_CR19","unstructured":"Standard for height level classification among children and adolescents aged 7~18\u00a0years,WS\/T 612\u20132018,National Health Commission of the People\u2019s Republic of China."},{"key":"3719_CR20","first-page":"461","volume":"58","author":"WQ Dai","year":"2020","unstructured":"Dai WQ, Gu XF. Yu YG [Exploring the clinical genetic characteristics and height for age growth curve of 210 patients with achondroplasia in China]. Zhonghua Er Ke Za Zhi. 2020;58:461\u20137.","journal-title":"Zhonghua Er Ke Za Zhi"},{"key":"3719_CR21","unstructured":"Li H, Ji C-y, Zong Xn, Zhang Y-Q. Height and weight standardized growth charts for Chinese children and adolescents aged 0 to 18\u00a0years. Chin J Pediatr 2009;47 7:487\u201392."},{"key":"3719_CR22","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1210\/jc.2018-00241","volume":"103","author":"KA Martin","year":"2018","unstructured":"Martin KA, Anderson RR, Chang RJ, et al. Evaluation and treatment of hirsutism in premenopausal women: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2018;103:1233\u201357.","journal-title":"J Clin Endocrinol Metab"},{"key":"3719_CR23","doi-asserted-by":"publisher","DOI":"10.1210\/jendso\/bvaf041","volume":"9","author":"S Reincke","year":"2025","unstructured":"Reincke S, Semler O, Jungh\u00e4nel-Welzing S, et al. Real-world outcome of vosoritide treatment in children with achondroplasia: a 12-month retrospective observational study. J Endocr Soc. 2025;9:bvaf041.","journal-title":"J Endocr Soc"},{"key":"3719_CR24","doi-asserted-by":"crossref","unstructured":"Cormier-Daire V, Edouard T, Isidor B, et al. Real-world safety and effectiveness of vosoritide in children with achondroplasia: French early access program. Horm Res Paediatr. 2025:1\u20139.","DOI":"10.1159\/000543743"},{"key":"3719_CR25","unstructured":"Savarirayan R, Bacino C, Carroll R, et al. P174: Early start, maximum impact: Long-term trial data supporting cumulative clinical benefit in children who initiated vosoritide <2\u00a0years old 2026. Available from: https:\/\/medical.biomarin.com\/en-us\/wp-content\/uploads\/sites\/2\/2026\/02\/ACMG_2026_Early_Start_poster_MED-SC-0265_MARCH-2026.pdf?v=1.17. Accessed 12 May 2026."},{"key":"3719_CR26","doi-asserted-by":"publisher","DOI":"10.1017\/erm.2012.4","volume":"14","author":"MB Laederich","year":"2012","unstructured":"Laederich MB, Horton WA. FGFR3 targeting strategies for achondroplasia. Expert Rev Mol Med. 2012;14:e11.","journal-title":"Expert Rev Mol Med"},{"key":"3719_CR27","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2201067119","volume":"119","author":"EL Schneider","year":"2022","unstructured":"Schneider EL, Carreras CW, Reid R, Ashley GW, Santi DV. A long-acting C-natriuretic peptide for achondroplasia. Proc Natl Acad Sci U S A. 2022;119:e2201067119.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"3719_CR28","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1016\/j.bone.2010.07.020","volume":"47","author":"S Pannier","year":"2010","unstructured":"Pannier S, Mugniery E, Jonquoy A, et al. Delayed bone age due to a dual effect of FGFR3 mutation in achondroplasia. Bone. 2010;47:905\u201315.","journal-title":"Bone"},{"key":"3719_CR29","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-019-1247-6","volume":"14","author":"C Saint-Laurent","year":"2019","unstructured":"Saint-Laurent C, Garde-Etayo L, Gouze E. Obesity in achondroplasia patients: from evidence to medical monitoring. Orphanet J Rare Dis. 2019;14:253.","journal-title":"Orphanet J Rare Dis"},{"key":"3719_CR30","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1093\/ajcn\/88.2.364","volume":"88","author":"JE Hoover-Fong","year":"2008","unstructured":"Hoover-Fong JE, Schulze KJ, McGready J, Barnes H, Scott CI. Age-appropriate body mass index in children with achondroplasia: interpretation in relation to indexes of height. Am J Clin Nutr. 2008;88:364\u201371.","journal-title":"Am J Clin Nutr"},{"key":"3719_CR31","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1016\/j.clinbiochem.2012.03.023","volume":"45","author":"MK Koivula","year":"2012","unstructured":"Koivula MK, Risteli L, Risteli J. Measurement of aminoterminal propeptide of type\u00a0I procollagen (PINP) in serum. Clin Biochem. 2012;45:920\u20137.","journal-title":"Clin Biochem"},{"key":"3719_CR32","doi-asserted-by":"publisher","DOI":"10.1016\/j.cca.2024.120067","volume":"567","author":"W Determe","year":"2025","unstructured":"Determe W, Hauge SC, Demeuse J, et al. Osteocalcin: a bone protein with multiple endocrine functions. Clin Chim Acta. 2025;567:120067.","journal-title":"Clin Chim Acta"},{"key":"3719_CR33","doi-asserted-by":"publisher","DOI":"10.1016\/j.gene.2020.144855","volume":"754","author":"S Vimalraj","year":"2020","unstructured":"Vimalraj S. Alkaline phosphatase: structure, expression and its function in bone mineralization. Gene. 2020;754:144855.","journal-title":"Gene"},{"key":"3719_CR34","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2024.108708","volume":"262","author":"YA Dickinson","year":"2024","unstructured":"Dickinson YA, Moyes AJ, Hobbs AJ. C-type natriuretic peptide (CNP): the cardiovascular system and beyond. Pharmacol Ther. 2024;262:108708.","journal-title":"Pharmacol Ther"},{"key":"3719_CR35","unstructured":"BioMarin Pharmaceutical Inc. Product Monograph Including Patient Medication Information: VOXZOGO\u00ae 2026. Available from: https:\/\/www.biomarin.com\/en-ca\/wp-content\/uploads\/sites\/4\/2026\/01\/Voxzogo-Canada-Product-Monograph-English.pdf. Accessed 12 May 2026."},{"key":"3719_CR36","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1159\/000506288","volume":"6","author":"CL Mei","year":"2020","unstructured":"Mei CL, Xue C, Yu SQ, et al. Executive summary: clinical practice guideline for autosomal dominant polycystic kidney disease in China. Kidney Dis. 2020;6:144\u20139.","journal-title":"Kidney Dis"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03719-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-026-03719-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03719-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,28]],"date-time":"2026-09-28T15:39:45Z","timestamp":1790609985000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-026-03719-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,28]]},"references-count":36,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["3719"],"URL":"https:\/\/doi.org\/10.1007\/s12325-026-03719-9","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,28]]},"assertion":[{"value":"12 April 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Lifen Chen, Xiaofei Zhang, Xiwen Zhang, Wenli Lu, Yuan Xiao, Fang Wang, Hanbing Shang, Yirong Yang, Ying Xu, Yuanyan Yang, Zhidong Gu, Xiaoyu Ma, Wen Su, and Zhiya Dong declare that they have no conflict of interest. In this study, BioMarin Pharmaceutical Inc. was not involved in research funding. BioMarin Pharmaceutical Inc. had no role in the interpretation of the data presented herein. All analyses, conclusions, and opinions expressed are solely those of the authors and do not necessarily reflect the views of BioMarin.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Ethics Review Committee of Ruijin Hospital (KY2024017), and a waiver of informed consent was granted in accordance with the committee\u2019s decision. The study was conducted in accordance with the principles of the Declaration of Helsinki of 1964 and its later amendments.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}